Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.

Journal: BMC cancer
Published Date: May 30, 2018

Abstract

BACKGROUND: Gene-expression companion diagnostic tests, such as the Oncotype DX test, assess the risk of early stage Estrogen receptor (ER) positive (+) breast cancers, and guide clinicians in the decision of whether or not to use chemotherapy. However, these tests are typically expensive, time consuming, and tissue-destructive.

Authors

  • Jon Whitney
    The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
  • German Corredor
    Universidad Nacional de Colombia, Bogotá D.C, Colombia.
  • Andrew Janowczyk
    Biomedical Engineering Department, Case Western Reserve University, Cleveland, Ohio.
  • Shridar Ganesan
    Department of Medicine, Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08903, USA.
  • Scott Doyle
    Department of Pathology and Anatomical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
  • John Tomaszewski
    Department of Pathology and Anatomical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
  • Michael Feldman
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine Philadelphia, PA, United States; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
  • Hannah Gilmore
    Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
  • Anant Madabhushi
    Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio.

Keywords

External Resources

Popular Topics
Recent Journals